Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial
(2012) In Europace 14(6). p.804-809- Abstract
- Vernakalant is a novel, relatively atrial-selective antiarrhythmic agent for conversion of atrial fibrillation (AF) to sinus rhythm. This study examined the safety and efficacy of vernakalant in converting atrial flutter (AFL) to sinus rhythm. This was a phase 2/3, randomized, double-blind, placebo-controlled trial. Adults with AFL received either a 10 min infusion of 3.0 mg/kg vernakalant (n 39) or placebo (n 15). If AFL or AF persisted at the end of a 15 min observation period, a second 10 min infusion of 2.0 mg/kg vernakalant or placebo was administered. The primary efficacy outcome was the proportion of patients who had treatment-induced conversion of AFL to sinus rhythm for a minimum duration of 1 min within 90 min after the start of... (More)
- Vernakalant is a novel, relatively atrial-selective antiarrhythmic agent for conversion of atrial fibrillation (AF) to sinus rhythm. This study examined the safety and efficacy of vernakalant in converting atrial flutter (AFL) to sinus rhythm. This was a phase 2/3, randomized, double-blind, placebo-controlled trial. Adults with AFL received either a 10 min infusion of 3.0 mg/kg vernakalant (n 39) or placebo (n 15). If AFL or AF persisted at the end of a 15 min observation period, a second 10 min infusion of 2.0 mg/kg vernakalant or placebo was administered. The primary efficacy outcome was the proportion of patients who had treatment-induced conversion of AFL to sinus rhythm for a minimum duration of 1 min within 90 min after the start of the first infusion. No patient in the placebo group met the primary outcome. Only one patient receiving vernakalant (1 of 39, 3) converted to sinus rhythm. A reduced mean absolute ventricular response rate occurred within 50 min in patients receiving vernakalant (mean change from baseline 8.2 b.p.m.) vs. patients receiving placebo (0.2 b.p.m.) (P 0.037). A post-hoc analysis revealed that vernakalant increased AFL cycle length by an average of 55 ms, whereas the AFL cycle length was unchanged in the placebo group (P 0.001). There was no occurrence of 1 : 1 atrio-ventricular conduction. Dysgeusia and sneezing were the most common treatment-related adverse events, consistent with previous reports. Vernakalant did not restore sinus rhythm in patients with AFL. Vernakalant modestly slowed AFL and ventricular response rates, and was well tolerated. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2906495
- author
- Camm, A. John ; Toft, Egon ; Torp-Pedersen, Christian ; Vijayaraman, Pugazhendhi ; Juul-Möller, Steen LU ; Ip, John ; Beatch, Gregory N. ; Dickinson, Garth and Wyse, D. George
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Atrial flutter, Antiarrhythmic drugs, Arrhythmia, Vernakalant
- in
- Europace
- volume
- 14
- issue
- 6
- pages
- 804 - 809
- publisher
- Oxford University Press
- external identifiers
-
- wos:000304531300008
- scopus:84861595308
- ISSN
- 1532-2092
- DOI
- 10.1093/europace/eur416
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)
- id
- 96ee8ce2-9496-420d-9683-b599d18ce6a6 (old id 2906495)
- date added to LUP
- 2016-04-01 10:30:22
- date last changed
- 2022-04-12 06:56:05
@article{96ee8ce2-9496-420d-9683-b599d18ce6a6,
abstract = {{Vernakalant is a novel, relatively atrial-selective antiarrhythmic agent for conversion of atrial fibrillation (AF) to sinus rhythm. This study examined the safety and efficacy of vernakalant in converting atrial flutter (AFL) to sinus rhythm. This was a phase 2/3, randomized, double-blind, placebo-controlled trial. Adults with AFL received either a 10 min infusion of 3.0 mg/kg vernakalant (n 39) or placebo (n 15). If AFL or AF persisted at the end of a 15 min observation period, a second 10 min infusion of 2.0 mg/kg vernakalant or placebo was administered. The primary efficacy outcome was the proportion of patients who had treatment-induced conversion of AFL to sinus rhythm for a minimum duration of 1 min within 90 min after the start of the first infusion. No patient in the placebo group met the primary outcome. Only one patient receiving vernakalant (1 of 39, 3) converted to sinus rhythm. A reduced mean absolute ventricular response rate occurred within 50 min in patients receiving vernakalant (mean change from baseline 8.2 b.p.m.) vs. patients receiving placebo (0.2 b.p.m.) (P 0.037). A post-hoc analysis revealed that vernakalant increased AFL cycle length by an average of 55 ms, whereas the AFL cycle length was unchanged in the placebo group (P 0.001). There was no occurrence of 1 : 1 atrio-ventricular conduction. Dysgeusia and sneezing were the most common treatment-related adverse events, consistent with previous reports. Vernakalant did not restore sinus rhythm in patients with AFL. Vernakalant modestly slowed AFL and ventricular response rates, and was well tolerated.}},
author = {{Camm, A. John and Toft, Egon and Torp-Pedersen, Christian and Vijayaraman, Pugazhendhi and Juul-Möller, Steen and Ip, John and Beatch, Gregory N. and Dickinson, Garth and Wyse, D. George}},
issn = {{1532-2092}},
keywords = {{Atrial flutter; Antiarrhythmic drugs; Arrhythmia; Vernakalant}},
language = {{eng}},
number = {{6}},
pages = {{804--809}},
publisher = {{Oxford University Press}},
series = {{Europace}},
title = {{Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial}},
url = {{http://dx.doi.org/10.1093/europace/eur416}},
doi = {{10.1093/europace/eur416}},
volume = {{14}},
year = {{2012}},
}